Skip to main content

Articles By Adela Castro, MD

back, LBP, spine, AS

Imaging in Axial Spondyloarthritis

The diagnosis of axial spondyloarthritis (axSpA) is clinical, however, there are still unmet needs, particularly in the diagnosis of early disease and evaluation of disease activity and progression. As imaging technology continues to evolve, its role in axSpA management is expected to expand, offering more precise, individualized care. Here are two studies presented at EULAR 2025.

Read Article
IL17

Expanding the IL-17 Therapeutic Landscape

IL-17 inhibitors are an effective therapeutic for a broad spectrum of inflammatory and autoimmune diseases and its blockade has revolutionized management of diseases such as psoriasis, psoriatic arthritis and SpA. Is there a need for more medications within the same therapeutic class?

Read Article
Kavanaugh RNL 25

Combination biologics in PsA: are we there yet?

Despite various and efficacious options for management of PsA there is still an unmet need for patients with inadequate responses to current therapies or difficult-to-treat disease. The role of dual biologic therapy targeting different inflammatory pathways has become an area of great interest in the field.

Read Article
AI

Will AI put me out of a job?

The development of AI and other technologies brings new possibilities for optimizing diagnosis, management and has potential for improving outcomes in RA. At RheumNow Live 2025, Dr. Jeff Curtis, University of Alabama at Birmingham, presented a talk on, "AI applied to Rheumatoid Arthritis Care: Practically (Not) Perfect".

Read Article
men and women

ICYMI: Sex related differences in PsA

Different factors are known to influence disease characteristics and outcomes in psoriatic arthritis (PsA).

Read Article
men and women

Sex related differences in PsA

Different factors are known to influence disease characteristics and outcomes in psoriatic arthritis (PsA).

Read Article
back, LBP, spine, AS

Difficult to Manage Axial Spondyloarthritis

Studies show that patients with difficult-to-manage axSpA have a higher disease activity; however, the lack of a consensus definition led researchers and clinicians to utilize their own proposed definition, resulting in variability of the characteristics of non-responders.

Read Article
×